NASDAQ:NBSENeuBase Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NeuBase Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.72 +0.28 (+3.76 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$7.44Now: $7.72▼$7.8150-Day Range$7.25MA: $8.72▼$11.5152-Week Range$4.15Now: $7.72▼$11.78Volume91,619 shsAverage Volume253,109 shsMarket Capitalization$178.49 millionP/E RatioN/ADividend YieldN/ABeta0.38 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its lead programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA); and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type 1 disease mRNA. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingNeuBase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.67, NeuBase Therapeutics has a potential upside of 102.9% from its current price of $7.72.Amount of Analyst CoverageNeuBase Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesNeuBase Therapeutics has received 32 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeuBase Therapeutics has received 25 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeuBase Therapeutics has received 56.14% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NeuBase Therapeutics and other stocks. Vote “Outperform” if you believe NBSE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBSE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeuBase Therapeutics does not currently pay a dividend.Dividend GrowthNeuBase Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuBase Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,843.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 24.00% of the stock of NeuBase Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.71% of the stock of NeuBase Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NeuBase Therapeutics are expected to decrease in the coming year, from ($0.97) to ($1.05) per share.Price to Book Value per Share RatioNeuBase Therapeutics has a P/B Ratio of 13.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.86 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBSE Previous Symbol CUSIPN/A CIKN/A Webwww.neubasetherapeutics.com Phone646-450-1790Debt Debt-to-Equity RatioN/A Current Ratio1.74 Quick Ratio1.74Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book13.08Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-26,960,000.00 Net MarginsN/A Return on Equity-446.35% Return on Assets-333.32%Miscellaneous Employees12 Outstanding Shares23,120,000Market Cap$178.49 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable $7.72 +0.28 (+3.76 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NBSE News and Ratings via Email Sign-up to receive the latest news and ratings for NBSE and its competitors with MarketBeat's FREE daily newsletter. NeuBase Therapeutics (NASDAQ:NBSE) Frequently Asked Questions How has NeuBase Therapeutics' stock been impacted by COVID-19 (Coronavirus)? NeuBase Therapeutics' stock was trading at $7.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NBSE shares have increased by 10.0% and is now trading at $7.72. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of NeuBase Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NeuBase Therapeutics. When is NeuBase Therapeutics' next earnings date? NeuBase Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for NeuBase Therapeutics. How were NeuBase Therapeutics' earnings last quarter? NeuBase Therapeutics (NASDAQ:NBSE) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.04. View NeuBase Therapeutics' earnings history. What price target have analysts set for NBSE? 6 equities research analysts have issued 1 year target prices for NeuBase Therapeutics' stock. Their forecasts range from $13.00 to $18.00. On average, they anticipate NeuBase Therapeutics' share price to reach $15.67 in the next twelve months. This suggests a possible upside of 102.9% from the stock's current price. View analysts' price targets for NeuBase Therapeutics. Has NeuBase Therapeutics been receiving favorable news coverage? Media stories about NBSE stock have been trending somewhat positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. NeuBase Therapeutics earned a news impact score of 1.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about NeuBase Therapeutics. Who are some of NeuBase Therapeutics' key competitors? Some companies that are related to NeuBase Therapeutics include Morphic (MORF), Omeros (OMER), Tricida (TCDA), ZIOPHARM Oncology (ZIOP), Frequency Therapeutics (FREQ), Akouos (AKUS), Homology Medicines (FIXX), ORIC Pharmaceuticals (ORIC), Eagle Pharmaceuticals (EGRX), Passage Bio (KROS), Kadmon (KDMN), Stemline Therapeutics (STML), Trillium Therapeutics (TRIL), Basilea Pharmaceutica (BPMUF) and Aprea Therapeutics (APRE). View all competitors. What other stocks do shareholders of NeuBase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Suncor Energy (SU), AT&T (T), AbbVie (ABBV), Walt Disney (DIS), Enbridge (ENB), Enterprise Products Partners (EPD), Energy Transfer LP Unit (ET), Roku (ROKU), Adobe (ADBE) and Alibaba Group (BABA). Who are NeuBase Therapeutics' key executives? NeuBase Therapeutics' management team includes the following people: Dr. Dietrich A. Stephan Ph.D., Founder, Pres, CEO & Chairman (Age 50, Pay $329.78k)Mr. Samuel Backenroth, CFO, Treasurer & Sec. (Age 36, Pay $337.16k)Dr. Danith H. Ly, Chief Scientific OfficerDr. Robert Friedlander M.D., Consulting Chief Medical OfficerDr. Robert Zamboni Ph.D., Chief of Preclinical Devel. What is NeuBase Therapeutics' stock symbol? NeuBase Therapeutics trades on the NASDAQ under the ticker symbol "NBSE." Who are NeuBase Therapeutics' major shareholders? NeuBase Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.02%), Strs Ohio (0.02%) and Heritage Wealth Advisors (0.00%). Company insiders that own NeuBase Therapeutics stock include Dietrich A Stephan, Eric I Richman and Samuel Backenroth. View institutional ownership trends for NeuBase Therapeutics. Which institutional investors are selling NeuBase Therapeutics stock? NBSE stock was sold by a variety of institutional investors in the last quarter, including Heritage Wealth Advisors. View insider buying and selling activity for NeuBase Therapeutics. Which institutional investors are buying NeuBase Therapeutics stock? NBSE stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, and Strs Ohio. Company insiders that have bought NeuBase Therapeutics stock in the last two years include Dietrich A Stephan, Eric I Richman, and Samuel Backenroth. View insider buying and selling activity for NeuBase Therapeutics. How do I buy shares of NeuBase Therapeutics? Shares of NBSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is NeuBase Therapeutics' stock price today? One share of NBSE stock can currently be purchased for approximately $7.72. How big of a company is NeuBase Therapeutics? NeuBase Therapeutics has a market capitalization of $178.49 million. NeuBase Therapeutics employs 12 workers across the globe. What is NeuBase Therapeutics' official website? The official website for NeuBase Therapeutics is www.neubasetherapeutics.com. How can I contact NeuBase Therapeutics? NeuBase Therapeutics' mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The company can be reached via phone at 646-450-1790 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
